univers
california
lo
angel
professor
medicin
william
pardridg
develop
molecular
trojan
hors
strategi
rna
interfer
rnai
deliveri
licens
drugdeliveri
specialist
armagen
technolog
santa
monica
california
consist
incorpor
either
peptid
monoclon
antibodi
target
membranebound
receptor
liposom
contain
plasmid
dna
desir
sirna
sequenc
lipid
coupl
polyethylen
glycol
prevent
nonspecif
fusion
cell
membran
nontarget
cell
strategi
aim
protect
dna
degrad
nucleas
ensur
sequenti
uptak
endocytosi
across
barrier
cell
nuclear
membran
neuron
system
test
adult
mice
rhesu
monkey
pardridg
hope
see
clinic
trial
brain
cancer
within
two
year
trojan
hors
also
featur
targetran
deliveri
system
intradigm
rockvil
maryland
targetran
involv
nanoparticl
form
selfassembl
posit
charg
polym
neg
charg
sirna
encas
protect
addit
ligand
ad
target
particular
tissu
intraven
inject
combin
sirna
use
inhibit
multipl
drug
target
one
intradigm
target
vascular
endotheli
growth
factor
vegf
pathway
involv
angiogenesi
tumour
diseas
martin
woodl
chief
scientif
offic
intradigm
hope
take
vegftarget
technolog
clinic
first
cancer
next
year
agerel
macular
degener
rel
common
caus
blind
involv
abnorm
blood
vessel
growth
retina
alnylam
cambridg
massachusett
also
develop
sirna
therapeut
condit
woodl
collabor
raymond
schiffel
netherland
cancer
institut
amsterdam
caution
mani
ligand
target
multipl
receptor
like
need
clinic
applic
rnai
cancer
human
far
complex
differ
phase
tumorigenesi
part
process
angiogen
intradigm
also
collabor
research
guang
zhou
hong
kong
beij
produc
rnaibas
therapi
coronaviru
caus
sever
acut
respiratori
syndrom
sar
juli
clayton
